Related Experiment Video
Updated: Apr 30, 2026
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.8K
Aldehyde dehydrogenase 2 activation in heart failure restores mitochondrial function and improves ventricular
Katia M S Gomes1, Juliane C Campos1, Luiz R G Bechara1
1Department of Anatomy, Institute of Biomedical Sciences, Paulo, Brazil.
Cardiovascular Research
|May 13, 2014
Summary
Chronic activation of aldehyde dehydrogenase 2 (ALDH2) with Alda-1 improved heart failure outcomes in rats. This treatment reduced cardiac dysfunction, prevented adverse remodelling, and enhanced mitochondrial function, suggesting therapeutic potential for heart failure.
Area of Science:
- Cardiovascular Biology
- Mitochondrial Medicine
- Pharmacology
Background:
- Mitochondrial aldehyde dehydrogenase 2 (ALDH2) plays a protective role against acute cardiac injury.
- Heart failure (HF) progression involves ventricular remodelling and cardiac dysfunction.
- Chronic aldehyde accumulation contributes to HF pathophysiology.
Purpose of the Study:
- To investigate the therapeutic benefits of chronic ALDH2 activation on established heart failure.
- To evaluate the effects of a selective ALDH2 activator (Alda-1) on post-myocardial infarction cardiac remodeling and function.
Main Methods:
- Rats with established heart failure (post-myocardial infarction) were treated with Alda-1 for 6 weeks.
- Cardiac function, cardiomyocyte mechanics, and cardiac remodeling markers were assessed.
- Mitochondrial function, oxidative stress markers, and cell death pathways were analyzed.
Main Results:
- Alda-1 treatment improved cardiac function, cardiomyocyte shortening, and diastolic properties.
- Sustained Alda-1 administration suppressed myocardial hypertrophy and fibrosis, indicating anti-remodeling effects.
- ALDH2 activation reduced aldehydic load, enhanced mitochondrial respiratory control, and decreased reactive oxygen species generation.
- Alda-1 treatment inhibited mitochondrial calcium overload and cytochrome c release, preserving mitochondrial integrity.
Conclusions:
- Selective activation of mitochondrial ALDH2 is sufficient to improve heart failure outcomes.
- ALDH2 activation mitigates the detrimental effects of aldehydic overload on mitochondrial bioenergetics and oxidative stress.
- Alda-1 demonstrates potential as a therapeutic agent for treating heart failure patients.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
1.8K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.8K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.8K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
01:30Heart Failure V: Medical Management
624
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
624
01:17Pathophysiology of Heart Failure
4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
01:29Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753